Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs

ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

Trial Details

NCT ID
NCT07861425
Phase
PHASE1
Sponsor
Acepodia Biotech, Inc.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ACE723
Locations (sample)
  • Nanjing, China|32.06167,118.77778
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Males or females aged 18 to 75 years
  • HCC that is unresectable or metastatic
  • Pathologically confirmed HCC
  • Barcelona Clinic Liver Cancer (BCLC) stage B or C

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →